Navigation Links
Immunetics Wins $2.8 Million Contract for New Type of HIV Test
Date:5/18/2010

Boston-based Immunetics won a $2.8 million contract from the National Institutes of Health to develop a new test for HIV that will prevent a false positive diagnosis in individuals who have received HIV vaccines in clinical trials. The vaccine response alone results in a false positive result with current HIV tests, resulting in erroneous diagnosis.

Boston, Mass (PRWEB) May 18, 2010 -- Immunetics, Inc. (Boston, MA) has been selected to receive a $2.8 million contract as part of the National Heart, Lung, and Blood Institute’s (NHLBI) Retrovirus Epidemiology Donor Study-II (REDS-II) project, a long term epidemiologic study of blood safety involving HIV and other infectious and non-infectious complications of blood transfusion.

The contract will be administered by Westat, a research organization based in Rockville, MD, which is the coordinating center for the REDS-II project. Under the contract, Immunetics will develop and supply a new test for HIV, which will uniquely distinguish individuals infected with HIV from those who have been immunized with experimental HIV vaccines in clinical trials. At present, vaccination leads to a false positive result on the current generation of HIV screening tests, a problem highlighted by recent publications in medical journals.

Clinical trials for HIV vaccines have involved thousands of vaccine recipients worldwide and continue to enroll more subjects, who stand to benefit from availability of the new test. The NHLBI initiated this project because it will provide a test which will be useful in screening blood donors in those regions of the world where HIV vaccine trials have been or are being conducted and to avoid the permanent deferral of those donors found not to be infected with HIV. Immunetics will work with a consortium of researchers at the National Institutes of Health, the Food and Drug Administration’s Center for Biologics Evaluation and Research where the original research leading to the new test was carried out, Blood Systems Research Institute in San Francisco, and others. The contract is valued at $9.2 million with all options exercised.

“This contract award presents a major opportunity for Immunetics and will leverage our longtime experience in the field of HIV diagnostics and assay development” said Dr. Andrew Levin, Immunetics' CEO and Scientific Director who will be the Principal Investigator on the project. “We see a great fit between our technology and the basic scientific advances made by the research teams at CBER and NIH. Given the vital need for an effective HIV vaccine, the test which we will be developing could play an essential role in current and future vaccine trials. We are particularly pleased to announce this award today, which has been designated by the NIH as National HIV Vaccine Awareness Day, and are very excited by the potential to make a significant contribution to public health in this area.”

Immunetics offers state-of-the-art assay technology for infectious disease diagnosis and pathogen detection, and for over ten years has been a leading innovator of tests for bacterial, viral and parasitic diseases. The company produces and markets a range of infectious disease assay kits and instruments. Its mission is better, cost-efficient care through more accurate diagnosis.

Contact: Andrew Levin - 617-896-9100 ext. 13 or alevin(at)immunetics(dot)com

# # #

Read the full story at http://www.prweb.com/releases/2010/05/prweb4015214.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Safe & Secure Online Pharmacy Viamedic.com; Reaches Milestone of 1.5 Million Orders Processed
2. More Than 1 Million Invitations Anticipated for National ‘Back To Church Sunday,' Set for Sept. 12
3. Millions Are Losing Their Hearing Unnecessarily; Noise-Induced Hearing Loss Is Always Preventable, Says HearUSA Audiologist
4. Infectious diseases caused two-thirds of the nearly 9 million child deaths globally in 2008
5. Enter One Year Auction Contest; You Could Win 5% of Winning Bid or Buy Now - $1 Million Option Proceeds
6. $18.5 Million New Jersey Medical Malpractice Birth Injury Verdict Due To Cerebral Palsy Caused By A Delayed C-Section
7. $1.9 million grant to help UCF find multiple sclerosis nerve-ana
8. NIH awards $2.7-million grant to Kent State to study cognitive impairment in heart failure patients
9. MU awarded $8.5 million to explore tiny vessels role in cardiovascular diseases
10. Hutchinson Center receives $10.24 million from NIH for Latina breast cancer research
11. NIH awards $10 million to Rush University Medical Center to address health disparities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... ... Edward D. Buckingham, M.D . is excited announce that he has been ... out by the National Consumer Advisory Board to honor excellence in medicine. Only doctors ... award. , The National Consumer Advisory Board (NCAB) is a private organization created to ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Clinical ... representatives from the Japan PMDA, US FDA, industry and academia at the ... help format data from clinical trials so that it can be shared and ...
(Date:5/23/2016)... ... May 23, 2016 , ... ComplianceOnline, the leading governance, ... host medical device summit on September 15 and 16, 2016 in San Diego, ... former FDA office bearers will be one of the largest gatherings of medical device ...
(Date:5/23/2016)... ... May 23, 2016 , ... In Pursuit of Balance (IPOB) co-founders Jasmine Hirsch ... operations at the end of 2016. , “We created IPOB to change the ... we look back on what we have achieved, we’re gratified by the response of ...
(Date:5/23/2016)... ... 2016 , ... Bio-Optronics, Inc. is delighted to announce recent ... recent and anticipated growth. , Max Elbaz was appointed as Vice President, Sales ... Max joined the Bio-Optronics team in March. His areas of expertise include international ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... , May 20, 2016 ... Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation ... Biological Drugs - This New Study Reveals Selling ... Ahead ,What is the future ... the latest technological and commercial analysis. Staying ahead ...
(Date:5/19/2016)... PARIS , May 19,2016 ... Activities at Digestive Disease Week Meeting and 91 ... Society Mauna Kea Technologies (Euronext: MKEA, ... laser endomicroscopy platform, today announced that its Cellvizio ... meeting focused on gastroenterology during the month of ...
(Date:5/19/2016)... , May 19, 2016 BioLight ... an emerging global ophthalmic company focused on the discovery, ... address ophthalmic conditions, announced today that it has obtained ... ) for the manufacturing, distribution, marketing and sales ... treatment of dry eye syndrome (DES) and other ophthalmic ...
Breaking Medicine Technology: